SEC Filing Summary for Arcellx, Inc.

This filing details transactions related to Arcellx, Inc. (ACLX) on April 28, 2026. Andrew H. Galligan, a director, reported the disposition of 5,000 shares of Common Stock held indirectly. Additionally, stock options to purchase 16,829 and 1,784 shares of Common Stock were disposed of. These transactions occurred in the context of a merger agreement with Gilead Sciences, Inc. Under the agreement, Arcellx, Inc. was acquired, with common stock tendered for $115.00 per share in cash plus one contingent value right. Stock options were canceled and converted into cash payments based on the difference between the exercise price and the closing amount, plus contingent value rights.